BACKGROUND: The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents may be associated with increased morbidity and mortality. This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning. STUDY DESIGN: A systematic review and meta-analysis of exercise tolerance and physical functioning. SETTING & PARTICIPANTS: Adults on maintenance dialysis therapy. SELECTION CRITERIA FOR STUDIES: Outcomes measured before and after ESA treatment were required. Studies of physical function were required to include at least 25 participants. INTERVENTION: Treatment with any ESA. OUTCOMES: Exercise tolerance measured using VO(2peak) (oxygen consumption per minute at the peak workload during the test), duration of exercise, or 6-minute walk distance or physical functioning assessed using > or = 1 patient- or clinician-reported outcome measure that included a physical function domain. RESULTS: 28 articles met criteria for inclusion for evaluation of exercise tolerance, and 14 articles, for physical function. Meta-analysis showed a 23.8% increase in VO(2peak) from before to after erythropoietin therapy initiation (15 studies) and a nonsignificant 8.2% increase comparing a higher with a lower hemoglobin target (3 studies). For physical functioning, 4 studies met criteria for inclusion in the meta-analysis: there was a 10.5% increase in Karnofsky score from before to after erythropoietin therapy initiation. LIMITATIONS: Many studies of exercise tolerance did not include control groups. A wide variety of instruments was used to assess physical function. CONCLUSIONS: Partial correction of anemia through ESA treatment has a consistent and positive impact on VO(2peak). ESA treatment improves patient- and clinician-assessed physical functioning. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND: The role of erythropoiesis-stimulating agents (ESAs) in treating the anemia of chronic kidney disease has been reevaluated in view of recent studies suggesting that the use of these agents may be associated with increased morbidity and mortality. This potential increased risk needs to be weighed against the potential benefit of ESAs in improving various aspects of health-related quality of life, in particular, exercise tolerance and physical functioning. STUDY DESIGN: A systematic review and meta-analysis of exercise tolerance and physical functioning. SETTING & PARTICIPANTS: Adults on maintenance dialysis therapy. SELECTION CRITERIA FOR STUDIES: Outcomes measured before and after ESA treatment were required. Studies of physical function were required to include at least 25 participants. INTERVENTION: Treatment with any ESA. OUTCOMES: Exercise tolerance measured using VO(2peak) (oxygen consumption per minute at the peak workload during the test), duration of exercise, or 6-minute walk distance or physical functioning assessed using > or = 1 patient- or clinician-reported outcome measure that included a physical function domain. RESULTS: 28 articles met criteria for inclusion for evaluation of exercise tolerance, and 14 articles, for physical function. Meta-analysis showed a 23.8% increase in VO(2peak) from before to after erythropoietin therapy initiation (15 studies) and a nonsignificant 8.2% increase comparing a higher with a lower hemoglobin target (3 studies). For physical functioning, 4 studies met criteria for inclusion in the meta-analysis: there was a 10.5% increase in Karnofsky score from before to after erythropoietin therapy initiation. LIMITATIONS: Many studies of exercise tolerance did not include control groups. A wide variety of instruments was used to assess physical function. CONCLUSIONS: Partial correction of anemia through ESA treatment has a consistent and positive impact on VO(2peak). ESA treatment improves patient- and clinician-assessed physical functioning. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Kirsten L Johansen; Glenn M Chertow; Nancy G Kutner; Lorien S Dalrymple; Barbara A Grimes; George A Kaysen Journal: Kidney Int Date: 2010-09-01 Impact factor: 10.612
Authors: Stefania S Grigoriou; Christina Karatzaferi; Christoforos D Giannaki; Gianna Patramani; Christina Vogiatzi; Georgia I Mitrou; Ioannis Stefanidis; Giorgos K Sakkas Journal: Int Urol Nephrol Date: 2022-07-05 Impact factor: 2.370
Authors: Fredric O Finkelstein; Kelli L Arsenault; Ana Taveras; Kwabena Awuah; Susan H Finkelstein Journal: Nat Rev Nephrol Date: 2012-10-23 Impact factor: 28.314
Authors: Cynthia B Whitman; Sanatan Shreay; Matthew Gitlin; Martijn G H van Oijen; Brennan M R Spiegel Journal: Clin J Am Soc Nephrol Date: 2013-08-08 Impact factor: 8.237